Enterprise Therapeutics Ltd announced that it has received £26 million in a round of funding led by new investor, Panakès Partners SGR SpA on January 30, 2024. The transaction included participation from returning investors, Versant Venture Management, LLC, Novartis Venture Fund, a fund managed by Novartis Venture Funds, Forbion Capital Partners B.V., Epidarex Capital and IP Group Plc. As part of the transaction, Rob Woodman of Panakès Partners SGR SpA joined the board of directors of the company.